JP6908805B2 - Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体 - Google Patents

Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体 Download PDF

Info

Publication number
JP6908805B2
JP6908805B2 JP2018524421A JP2018524421A JP6908805B2 JP 6908805 B2 JP6908805 B2 JP 6908805B2 JP 2018524421 A JP2018524421 A JP 2018524421A JP 2018524421 A JP2018524421 A JP 2018524421A JP 6908805 B2 JP6908805 B2 JP 6908805B2
Authority
JP
Japan
Prior art keywords
disease
acid
benzofuran
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018524421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501875A (ja
JP2019501875A5 (enExample
Inventor
ジョン シー． ワーナー，
ジョン シー． ワーナー，
スリニバサ アール． チェルク，
スリニバサ アール． チェルク，
ジェフリー エー． グラッディング，
ジェフリー エー． グラッディング，
Original Assignee
アンビエント フォトニクス， インコーポレイテッド
アンビエント フォトニクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンビエント フォトニクス， インコーポレイテッド, アンビエント フォトニクス， インコーポレイテッド filed Critical アンビエント フォトニクス， インコーポレイテッド
Publication of JP2019501875A publication Critical patent/JP2019501875A/ja
Publication of JP2019501875A5 publication Critical patent/JP2019501875A5/ja
Application granted granted Critical
Publication of JP6908805B2 publication Critical patent/JP6908805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2018524421A 2015-11-11 2016-11-10 Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体 Active JP6908805B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253903P 2015-11-11 2015-11-11
US62/253,903 2015-11-11
PCT/US2016/061281 WO2017083488A1 (en) 2015-11-11 2016-11-10 Benzofuran derivatives for the treatment of cns and other disorders

Publications (3)

Publication Number Publication Date
JP2019501875A JP2019501875A (ja) 2019-01-24
JP2019501875A5 JP2019501875A5 (enExample) 2019-12-26
JP6908805B2 true JP6908805B2 (ja) 2021-07-28

Family

ID=58695297

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018524421A Active JP6908805B2 (ja) 2015-11-11 2016-11-10 Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体

Country Status (8)

Country Link
US (1) US10590100B2 (enExample)
EP (1) EP3374354B1 (enExample)
JP (1) JP6908805B2 (enExample)
CN (1) CN108699019B (enExample)
AU (1) AU2016353004B2 (enExample)
CA (1) CA3005212C (enExample)
IL (1) IL259674B (enExample)
WO (1) WO2017083488A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208712A1 (en) 2017-05-09 2018-11-15 Warner Babcock Insitute For Green Chemistry, Llc Stilbene and fused stilbene derivatives as solar cell dyes
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
EP3820465B1 (en) * 2018-07-10 2025-09-17 Ambient Photonics, Inc. Solar cell dyes for copper redox based dye sensitized solar cells and combinations thereof
TWI824012B (zh) * 2019-09-20 2023-12-01 美商安畢特光學公司 用於基於銅氧化還原的染料敏化太陽能電池的太陽能電池染料及其組合
WO2026055841A1 (zh) * 2024-09-11 2026-03-19 凯思凯迪(上海)医药科技股份有限公司 芳环并杂环类化合物、其制备方法和其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1349453A (en) * 1918-01-09 1920-08-10 James H Hall Trap
US1348677A (en) * 1919-10-04 1920-08-03 Claude A Witter Process of manufacturing metallic shapes
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
BE787576A (fr) * 1971-08-13 1973-02-14 Hoechst Ag Derives de benzofuranne et leur utilisation comme azureurs optiques
LU85544A1 (fr) * 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
JPS63139180A (ja) 1986-12-02 1988-06-10 Tanabe Seiyaku Co Ltd カルボン酸誘導体
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
CA2549736A1 (en) 2003-12-05 2005-06-23 The University Of North Carolina At Chapel Hill Cationic substituted benzofurans as antimicrobial agents
US7473786B1 (en) * 2003-12-05 2009-01-06 University Of Massachusetts Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts
SE0403006D0 (sv) * 2004-12-09 2004-12-09 Biovitrum Ab New compounds
GB0505725D0 (en) * 2005-03-19 2005-04-27 Merck Sharp & Dohme Therapeutic agents
AU2007209981B2 (en) 2006-02-01 2011-11-24 Merck Sharp & Dohme Corp. Potassium channel inhibitors
TW200930369A (en) * 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
US20090163586A1 (en) * 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
JP2012184224A (ja) * 2011-02-17 2012-09-27 Toho Univ Foundation アミロイドβタンパク質凝集阻害活性を有する化合物又はその薬理学的に許容し得る塩及びその製造方法、並びに、その用途
WO2013040528A1 (en) * 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
AU2013323198B2 (en) * 2012-09-28 2018-03-29 Srinivasa R. Cheruku Dihydro-6-azaphenalene derivatives for the treatment of CNS, oncological diseases and related disorders

Also Published As

Publication number Publication date
JP2019501875A (ja) 2019-01-24
IL259674B (en) 2021-07-29
US10590100B2 (en) 2020-03-17
EP3374354B1 (en) 2022-09-28
IL259674A (en) 2018-07-31
CN108699019A (zh) 2018-10-23
EP3374354A1 (en) 2018-09-19
CA3005212C (en) 2024-01-23
WO2017083488A1 (en) 2017-05-18
AU2016353004B2 (en) 2020-11-05
EP3374354A4 (en) 2019-07-17
AU2016353004A1 (en) 2018-06-14
CA3005212A1 (en) 2017-05-18
US20180346433A1 (en) 2018-12-06
CN108699019B (zh) 2022-05-10

Similar Documents

Publication Publication Date Title
JP2026053405A (ja) 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
KR102536408B1 (ko) Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드
JP6908805B2 (ja) Ｃｎｓおよび他の障害の処置のためのベンゾフラン誘導体
JP6080947B2 (ja) Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するための化合物および組成物
JP2021119191A (ja) がんを処置するための組合せ治療
CA2857689C (en) Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
KR20150020170A (ko) Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
KR20150020169A (ko) Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
EP3114121A1 (en) Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
CN112261941A (zh) 可用作线粒体解偶联剂的氨基吡嗪及相关化合物
JP2025504963A (ja) Ａｍｐｋアゴニスト及びその使用方法
JP2022521491A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
KR20190026841A (ko) sGC 자극제의 인 전구약물
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
AU2018306726A1 (en) Anticancer drugs and methods of making and using same
US11286233B2 (en) Stilbene derivatives for the treatment of CNS and other disorders
JP2025535057A (ja) フェニルオキシアミドキナーゼ阻害剤
JP7186874B2 (ja) ピラゾリル化合物およびその使用方法
CN107304200B (zh) 一种新的喜巴辛类似物及其在医药中的应用
CN107304199B (zh) 一种新的喜巴辛类似物及其在医药中的应用
KR20200022628A (ko) 페닐아세트산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
JP7677646B2 (ja) 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤
EP3263567A1 (en) Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof
WO2025193111A1 (en) An imidazole-indole derivative binding to 5-ht7 serotonin receptor, a pharmaceutical composition comprising the derivative, uses of the derivative and the composition, and an intermediate product for manufacturing the imidazole-indole derivative
CN103958501B (zh) 苯并七元杂环类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210408

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210618

R150 Certificate of patent or registration of utility model

Ref document number: 6908805

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250